RT Journal Article
SR Electronic
T1 Dapagliflozin (SGLT2-i) induced euglycaemic diabetic ketoacidosis
JF BMJ Case Reports
JO BMJ Case Reports
FD BMJ Publishing Group Ltd
SP e231104
DO 10.1136/bcr-2019-231104
VO 12
IS 9
A1 Ross Leader
A1 Jake Cowen
A1 Surya Panicker Rajeev
YR 2019
UL http://casereports.bmj.com/content/12/9/e231104.abstract
AB Sodium glucose co-transporter-2 inhibitors (SGLT2-i) have become a popular therapeutic strategy in the management of hyperglycaemia in type 2 diabetes mellitus. The primary site of action of SGLT2-i is at the proximal renal convoluted tubule. They work by blocking SGLT2 receptors, sodium-dependent glucose co-transport molecules, which in turn prevents glucose reabsorption, facilitating glucosuria, improving glycaemic control as well as a moderate degree of weight loss. We report the case of a 51-year-old woman admitted to the acute medical unit with abdominal pain and vomiting, who was diagnosed with euglycaemic diabetic ketoacidosis secondary to recent initiation of an SGLT2-i medication (dapagliflozin). Clinicians should be aware of this rare side effect of SGLT2-i, to circumvent delays in patient management.